26P Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to cabozantinib (CABO) plus durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the phase II ARCADIA trial)

V Huber,A Mereu,L Lalli,J Salsetta,C Banfi,P Squarcina,F Sgambelluri,R Mortarini,M Stellato,D Raggi,V Guadalupi,M Claps,W Ferrari Bravo,G Calareso,A Alessi,A Anichini,G Procopio,A Necchi,L Rivoltini,P Giannatempo

doi:10.1016/j.iotech.2023.100495

26P Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to cabozantinib (CABO) plus durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the phase II ARCADIA trial)

V Huber, A Mereu + Show 18 more

https://doi.org/10.1016/j.iotech.2023.100495

Copy DOI

Journal: Immuno-Oncology and Technology

Publication Date: Dec 1, 2023

Affiliation: Fondazione IRCCS Istituto Nazionale dei Tumori, IRCCS Ospedale San Raffaele

#Advanced Urothelial Carcinoma #Advanced Urothelial Carcinoma Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

26P Liquid biopsy as promising source of plasma extracellular vesicle biomarkers of response to cabozantinib (CABO) plus durvalumab (DURVA) in advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) patients (the phase II ARCADIA trial)

Full Text